These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 2611446

  • 1. Acute effect of the intranasal administration of salmon calcitonin in osteoporotic women.
    Vega E, Gonzalez D, Ghiringhelli G, Mautalen C.
    Bone Miner; 1989 Nov; 7(3):267-73. PubMed ID: 2611446
    [Abstract] [Full Text] [Related]

  • 2. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 3. A double-blind, placebo-controlled, dose-finding trial of intermittent nasal salmon calcitonin for prevention of postmenopausal lumbar spine bone loss.
    Reginster JY, Deroisy R, Lecart MP, Sarlet N, Zegels B, Jupsin I, de Longueville M, Franchimont P.
    Am J Med; 1995 May; 98(5):452-8. PubMed ID: 7733123
    [Abstract] [Full Text] [Related]

  • 4. Comparison of the acute effect of the intranasal and intramuscular administration of salmon calcitonin in Paget's disease.
    González D, Vega E, Ghiringhelli G, Mautalen C.
    Calcif Tissue Int; 1987 Dec; 41(6):313-5. PubMed ID: 3124939
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Acute antiosteoclastic effect of salmon calcitonin in osteoporotic women.
    González D, Ghiringhelli G, Mautalen C.
    Calcif Tissue Int; 1986 Feb; 38(2):71-5. PubMed ID: 3082496
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group.
    Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D.
    Am J Med; 2000 Sep; 109(4):267-76. PubMed ID: 10996576
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Salmon calcitonin treatment by nasal spray in primary hyperparathyroidism.
    Tørring O, Bucht E, Sjöstedt U, Sjöberg HE.
    Bone; 1991 Sep; 12(5):311-6. PubMed ID: 1782100
    [Abstract] [Full Text] [Related]

  • 10. The effect of rectal and nasal administration of salmon calcitonin in normal subjects.
    Buclin T, Randin JP, Jacquet AF, Azria M, Attinger M, Gomez F, Burckhardt P.
    Calcif Tissue Int; 1987 Nov; 41(5):252-8. PubMed ID: 3121149
    [Abstract] [Full Text] [Related]

  • 11. Acute effects of nasal salmon calcitonin on calcium and bone metabolism.
    Thamsborg G, Skousgaard SG, Daugaard H, Schifter S, Kollerup G, Sørensen OH.
    Calcif Tissue Int; 1993 Oct; 53(4):232-6. PubMed ID: 8275350
    [Abstract] [Full Text] [Related]

  • 12. Preventive treatment of cortical bone loss with salmon nasal calcitonin in early postmenopausal women.
    Mango D, Ricci S, Manna P, Natili G, Dell'Acqua S.
    Minerva Endocrinol; 1993 Sep; 18(3):115-21. PubMed ID: 8183178
    [Abstract] [Full Text] [Related]

  • 13. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
    Agnusdei D, Gonnelli S, Camporeale A, Batignani T, Nardi P, Ianes A, Gennari C.
    Minerva Endocrinol; 1989 Sep; 14(3):169-76. PubMed ID: 2695815
    [Abstract] [Full Text] [Related]

  • 14. Comparison of cyclic and continuous calcitonin regimens in the treatment of postmenopausal osteoporosis.
    Tekeoğlu I, Adak B, Budancamanak M, Demirel A, Ediz L.
    Rheumatol Int; 2005 Dec; 26(2):157-61. PubMed ID: 15660234
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover.
    Tankó LB, Bagger YZ, Alexandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C.
    J Bone Miner Res; 2004 Sep; 19(9):1531-8. PubMed ID: 15312255
    [Abstract] [Full Text] [Related]

  • 16. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
    Ofluoglu D, Karadag-Saygi E, Canbulat C, Gunduz OH, Kul-Panza E, Akyuz G.
    Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
    [Abstract] [Full Text] [Related]

  • 17. Discontinuous calcitonin treatment of established osteoporosis--effects of withdrawal of treatment.
    Overgaard K, Hansen MA, Nielsen VA, Riis BJ, Christiansen C.
    Am J Med; 1990 Jul; 89(1):1-6. PubMed ID: 2152594
    [Abstract] [Full Text] [Related]

  • 18. Biochemical responses to sequential human parathyroid hormone (1-38) and calcitonin in osteoporotic patients.
    Hodsman AB, Fraher LJ.
    Bone Miner; 1990 May; 9(2):137-52. PubMed ID: 2161692
    [Abstract] [Full Text] [Related]

  • 19. Effects of nasal administration of calcitonin in oophorectomized women: 2-year controlled double-blind study.
    Grigoriou O, Papoulias I, Vitoratos N, Papadias C, Konidaris S, Antoniou G, Chryssikopoulos A.
    Maturitas; 1997 Dec 15; 28(2):147-51. PubMed ID: 9522322
    [Abstract] [Full Text] [Related]

  • 20. Calcitonin load test to assess the efficacy of salmon calcitonin.
    Stepan JJ, Zikán V.
    Clin Chim Acta; 2003 Oct 15; 336(1-2):49-55. PubMed ID: 14500034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.